Smith & Nephew (LON:SN) Price Target Lowered to GBX 1,290 at JPMorgan Chase & Co.

by · The Markets Daily

Smith & Nephew (LON:SN – Get Free Report) had its price objective dropped by equities researchers at JPMorgan Chase & Co. from GBX 1,438 to GBX 1,290 in a report released on Thursday,London Stock Exchange reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 14.97% from the company’s previous close.

Other research analysts have also issued research reports about the company. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 price objective on shares of Smith & Nephew in a research report on Tuesday, July 21st. Jefferies Financial Group restated a “buy” rating and issued a GBX 1,500 target price on shares of Smith & Nephew in a report on Wednesday. Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,350 target price on shares of Smith & Nephew in a research note on Monday, June 29th. Finally, Berenberg Bank reissued a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of GBX 1,172.56.

View Our Latest Analysis on SN

Smith & Nephew Price Performance

Shares of LON SN opened at GBX 1,122 on Thursday. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The company’s 50-day simple moving average is GBX 1,135.98 and its 200-day simple moving average is GBX 1,194.09. The stock has a market cap of £12.30 billion, a PE ratio of 40.40, a P/E/G ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Recommended Stories